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MHC class I-like CD1 molecules have evolved to present lipid-based
antigens to T cells. Differences in the antigen-binding clefts of the
CD1 family members determine the conformation and size of the
lipids that are presented, although the factors that shape
CD1 diversity remain unclear. In mice, two homologous genes,
CD1D1 and CD1D2, encode the CD1d protein, which is essential to
the development and function of natural killer T (NKT) cells. How-
ever, it remains unclear whether both CD1d isoforms are equivalent
in their antigen presentation capacity and functions. Here, we re-
port that CD1d2 molecules are expressed in the thymus of some
mouse strains, where they select functional type I NKT cells. Intrigu-
ingly, the T cell antigen receptor repertoire and phenotype of
CD1d2-selected type I NKT cells in CD1D1−/− mice differed from
CD1d1-selected type I NKT cells. The structures of CD1d2 in com-
plex with endogenous lipids and a truncated acyl-chain analog of
α-galactosylceramide revealed that its A′-pocket was restricted
in size compared with CD1d1. Accordingly, CD1d2 molecules
could not present glycolipid antigens with long acyl chains effi-
ciently, favoring the presentation of short acyl chain antigens.
These results indicate that the two CD1d molecules present dif-
ferent sets of self-antigen(s) in the mouse thymus, thereby
impacting the development of invariant NKT cells.
CD1 | MHC | NKT
CD1 molecules are glycoproteins that adopt an MHC class I-likestructure (1). In contrast to the polymorphic MHC molecules
that present peptides, CD1 molecules exhibit limited poly-
morphism and are ideally suited to present lipid-based antigens
(2). Based on sequence homology, function, and tissue distribu-
tion, the CD1 family has been classified into three distinct groups:
group I, includes CD1a, -b, and -c; group II consists of CD1d, and
group III is composed of CD1e (3). The number of CD1 isoforms
expressed in any given mammal varies considerably, however. For
example, humans express all five CD1 isoforms, rabbits lack CD1c,
and mice express only the CD1d protein. However, the basis for
such varied usage of genes within the CD1 locus across mammals
is largely unknown, but presumably reflects important functional
differences related to pathogen-driven evolutionary pressures.
Lipid antigen-loaded CD1d molecules are recognized by a
population of innate-like T lymphocytes, the natural killer T
(NKT) cells. Two broad classes of NKT cells, termed type I and
type II, have been defined on the basis of T cell antigen receptor
(TCR) expression and antigen reactivity (4). Type I NKT cells or
invariant NKT cells (iNKT) typically express a TCR that is the
product of a canonical rearrangement between the Vα14 gene
segment (Vα24 in human) and frequently the Jα18 gene segment,
with a complementarity determining region (CDR)-3α invariant at
the amino acid level (5, 6). In mice, the Vα14 invariant chain is
coexpressed with a limited set of Vβ chains, predominantly Vβ8.2,
Vβ7, and Vβ2, with variable CDR3β loop sequences (7). Essentially
all of these cells are responsive to the prototypical antigen
α-galactosylceramide (αGC) when presented by CD1d mole-
cules, irrespective of their TCRβ repertoire diversity (8–10). How
variation in CD1d itself impacts on type I NKT cell repertoire and
function remains unclear, however.
Upon antigenic stimulation, type I NKT cells respond rapidly by
producing Th1, Th2, and Th17 cytokines, and can also be cytotoxic
(11, 12). Type I NKT cells can be activated by bacterial ligands,
and sense changes in host lipid metabolism through recognition of
transiently expressed endogenous lipids (13–15). Chronic stimu-
lation by these “autoantigens” leads some type I NKT cells to
produce cytokines at steady state, which, in turn, influences the
development and activation of surrounding cells (16, 17). Thus,
their unique properties establish type I NKT cells as important
regulators of immune responses and tissue homeostasis (18).
In mice, two genes encoding the CD1d isoform have been
identified, CD1D1 and CD1D2. These two genes are located on
chromosome 3 and are approximately 9 kb apart, arranged in
opposite transcriptional orientation (19). The two genes share
95% sequence homology with each other, and are likely the
product of gene duplication (2, 20). Mouse CD1d molecules are
expressed primarily by cells of the hematopoietic lineage, in-
cluding B and T cells, macrophages, and dendritic cells (21, 22).
At the transcriptional level, CD1D1 is expressed at higher levels
than CD1D2 in all tissues tested except the thymus, where the
mRNA levels appear to be equal for both genes (19). Of the
17 amino acid differences between CD1d1 and CD1d2 proteins,
9 occur within the antigen-binding cleft, which includes a
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Cys168→Trp168 mutation. The cysteine 168 residue participates
in an intradomain disulfide bond that is highly conserved in
classical and nonclassical MHC I molecules (1, 19, 23), and is
thought to be critical for the folding of MHC-I (24, 25). The
impact of this mutation on CD1d2 structure and function is
unknown. Interestingly, the bovine CD1d gene (26) and the
primordial CD1-encoding gene found in chickens (27) also
contain an amino acid change at position 168. This change was
previously shown to affect the nature of the antigens presented
by these molecules (2). Intriguingly, rats possess only one CD1D
gene, which, based on sequence homology, more resemble
mouse CD1D1 than CD1D2, with a cysteine at position 168 (28).
It remains unclear what advantage, if any, the gene duplication
event that led to the existence of CD1D2 in the mouse might be.
The development of type I NKT cells requires expression of
CD1d by cortical thymocytes (29) and is impaired in mice lacking
CD1d expression. Interestingly, even though some targeting
strategies led to the disruption of both CD1D genes (30, 31), one
particular strain of CD1D-deficient mice, which was generated by
using embryonic stem cells of 129/Sv origin and has been largely
distributed in the scientific community and used in multiple
studies, disrupted only the CD1D1 gene (32). Furthermore, se-
quencing of the CD1D2 gene from C57BL/6 mice revealed a
frame-shift mutation at the beginning of the fourth exon
encoding the α3 domain, thereby abolishing CD1d2 protein ex-
pression in this strain (22). Altogether, these results contributed
to the assumption that CD1d2 molecules do not play any role in
the development of type I NKT cells. Earlier studies that iden-
tified type I NKT cells by using costaining for TCRβ chains and
the NK1.1 marker concurred with this notion (33). However, it
remains unknown whether the CD1D2 gene is mutated in other
strains of mice and whether its gene product might play a role in
the selection and function of iNKT cells.
Here we report that CD1d2 molecules are expressed in the
thymus of CD1D1−/−-deficient mice (32), where they select
functional type I NKT cells. High-throughput sequencing of
CD1D gene transcripts from the thymus of BALB/c mice showed
a transcript ratio of CD1D1:CD1D2 close to 1:1, supporting the
possibility for a role of CD1d2 in shaping the development of
iNKT cells. The CD1d2 crystal structures revealed that CD1d2 adopts
an overall architecture similar to CD1d1 and that the Cys168Trp
mutation does not collapse the antigen-binding groove. How-
ever, the CD1d2 A′-pocket was markedly restricted in size,
thereby favoring the loading of lipid antigens with shorter acyl-
chain length, as shown by the structure of CD1d2 in complex
with a truncated acyl chain (C10) analog of α-GC. Collectively,
our results demonstrate that CD1d2 is expressed in the thymus
of some mouse strains, where it likely presents a different
repertoire of self-antigens than CD1d1 and can thereby impact
the selection of iNKT cells and their function.
Results
Vα14-Jα18 TCR Usage in Conventional CD4+ and CD8+ T Cells from
CD1D1−/− Mice. We wanted to determine the frequency of the
Vα14–Jα18 rearrangement within conventional CD4+ and CD8+
TCRβ+ T cells. To ensure that CD4+ and CD8+ cell populations
would be devoid of any potentially contaminating iNKT cells, we
sorted cells from the spleens of C57BL/6 CD1D1−/− TCRCα+/−
mice by flow cytometry. The frequency of gene usage was measured
by quantitative PCR and normalized to the levels found in PBS57-
CD1d tetramer+ TCRβ+ cells sorted from the spleen of CD1D1+/−
TCRCα+/− mice. The strategy of amplification is depicted in SI
Appendix, Fig. S1. As seen in Fig. 1A, 2–3% of conventional T cells
use the Vα14 gene segment. Conventional splenic CD8+ T cells that
use the Vα14 gene segment appear to only very rarely rearrange
with the Jα18 gene segment, as revealed by the use of a Jα18-specific
probe. Surprisingly, the situation appeared different for CD4+
T cells, in which the results suggested that all Vα14 segments were
rearranged with Jα18, like in iNKT cells. Sequencing of the PCR
product showed that it corresponded to the canonical Vα14–Jα18
iNKT rearrangement. These perplexing results suggested that,
within the CD4+ T cells derived from CD1D1-deficient mice, Vα14
might have preferentially rearranged with Jα18, contradicting
previous findings showing that Vα14 can rearrange with all Jα
segments (34, 35). An alternative explanation could be provided if
some residual iNKT cells were still present in the sample of the
sorted CD4+ T cells from CD1D1−/− TCRCα+/− mice. Indeed,
upon careful flow cytometry analysis involving the acquisition of
several millions of events, we clearly detected a population of
PBS57-CD1d1 tetramer+ cells in the thymus, spleen, and liver
of CD1D1−/− mice (Fig. 1B). This population was absent from the
organs of CD1D1/CD1D2−/−mice and greatly decreased in Jα18−/−
mice, which lack the invariant Traj18 gene segment (36, 37). The few
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Fig. 1. Frequency of Vα14 usage and Vα14-Jα18 rearrangement usage among
CD4+ and CD8+ T cells purified from the spleen of CD1D1−/−mice and frequency
of iNKT cells in CD1D1−/− mice. (A) Relative frequency of Vα14 and Vα14-
Jα18 usage in CD4+ and CD8+ T cells from CD1D1−/− mice. The frequency was
normalized to the amount of the various PCR products found in iNKT cells
sorted from the spleen of CD1D1+/− TCRα+/− mice, which was set at 100%. Re-
sults are shown as mean ± SD. (B) Cells from the thymus, spleen, and liver of 6–
8-wk-old C57BL/6, CD1D1−/−, CD1D1D2−/−, and Jα18−/− mice were stained with
CD1d1 tetramers loaded with PBS57 (PBS57-CD1d), and TCRβ mAbs and ana-
lyzed by flow cytometry (data representative of n ≥ 3 per group across two
experiments). The percentage of iNKT cells in each sample is shown. (C) Sum-
mary of the data shown in B with percentage of iNKT cells in thymus, spleen,
and liver of 6–8-wk-old C57BL/6, CD1D1−/−, CD1D1D2−/−, and Jα18−/−mice (*P <
0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; ns, not significant).
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cells that were labeled in Jα18−/− mice likely correspond to the
atypical iNKT cells previously identified in that strain (37, 38). These
results contrast with previous experiments that examined the pres-
ence of NKT cells in CD1D1−/− mice by using TCRβ+ and NK1.1+
costaining and concluded that CD1d2 expression could not rescue
NKT cell development (33). Instead, our results demonstrate that,
even though the proportion of iNKT cells in CD1D1−/−mice is only
1–4% of the iNKT cells found in the organs of C57BL/6 (B6) mice
(Fig. 1C), CD1D1−/− mice should not be considered as iNKT cell-
deficient, and CD1d2 molecules can potentially select for iNKT cells.
The CD1D2 Sequence from CD1D1−/−Mice and the WT BALB/c Strain Is
Functional. B6 mice harbor a point mutation in exon 4 of CD1D2,
which encodes the α3 domain (22). This frame-shift mutation in-
troduces a stop codon, abolishing surface expression of the mol-
ecule. In the 129/sv strain, however, CD1D2 does not contain this
mutation (22). To confirm that CD1D2 in the CD1D1−/−mice (32)
is not the pseudogene found in the B6 mice, we designed primers
that span part of exon 4 and the adjoining intronic area. Genomic
DNA from CD1D1−/− mice, B6 mice, and another WT strain,
BALB/c, was purified and used for amplification of the exon
4 fragment. Sequencing results confirmed that, whereas the B6-
derived sequence contains a stop codon in exon 4, BALB/c and
129/Sv-derived CD1D1−/− mice had a functional CD1D2 se-
quence. These results demonstrate that no cross-over of the CD1
locus ever occurred during the backcross of the CD1D1−/−mice to
B6 mice and that the CD1 locus is of 129/sv origin in these mice.
Furthermore, these results suggest that CD1d2 molecules have the
potential to be expressed in BALB/c mice.
CD1d2 Protein Is Expressed in the Thymus but Not the Periphery of
CD1D1−/− Mice. Because no serological reagent currently exists to
discriminate CD1d1 from CD1d2 proteins, we first examined
CD1d2 expression on cells derived from B6 CD1D1−/− mice.
Controls were provided by staining cells from double-deficient
CD1D1/CD1D2 mice (30, 33) and heterozygous CD1D1+/− mice
generated by crossing CD1D1−/− mice with B6 mice. In this latter
strain, the CD1d protein levels represent the combined gene ac-
tivity of a single copy of CD1D1 B6 allele (because CD1D2 is
mutated in B6) and a single copy of the functional CD1D2 allele
from the KOmice (because CD1D1 has been knocked out in these
mice and the CD1D2 allele is of 129/Sv origin). As seen in Fig. 2,
we observed a low level of CD1d expression in the thymus of
CD1D1−/− mice, attributable to CD1d2 expression (Fig. 2A). In
particular, whereas CD1D1+/− thymocytes displayed hap-
loinsufficient patterns, expressing half the amount of CD1d found
on thymocytes from WT mice [as measured by geometric mean
fluorescence intensity (gMFI)], the CD1D1−/− thymocytes
expressed only 1/25 of the level expressed in WT mice (Fig. 2C).
Interestingly, this expression was limited to the thymus, in agree-
ment with previous results (33). In the periphery, we observed no
protein expression of CD1d2 on whole splenocytes or individual
splenic populations (Fig. 2 B and D).
Early experiments with the use of RNase protection assays
suggested that CD1D2-encoding transcripts were equally abun-
dant compared with CD1D1 transcripts in BALB/c thymocytes
(19). To verify these findings, we generated cDNA from B6 and
BALB/c DP thymocytes and amplified a portion of exon 2 by
using primers targeting identical sequences between CD1D1 and
CD1D2 genes. This segment of DNA, however, contains eight
nucleotide polymorphisms between the two genes. PCR products
were sequenced by using high-throughput sequencing, and the
relative expression of CD1D1 and CD1D2 transcripts was de-
termined in each strain. The transcript ratio of CD1D1 to
CD1D2 was overwhelmingly skewed toward CD1D1 in B6, with
an expression ratio close to 5:1. This likely reflects the degra-
dation of CD1D2-encoding mRNA as a result of nonsense-
mediated mRNA decay (39). In BALB/c, however, the ratio of
CD1D1:CD1D2 is close to 1:1 (Fig. 2E). Altogether, these results
demonstrate that CD1d2 molecules can be expressed in the
thymus of mice with a functional CD1D2 gene.
Development and Repertoire of CD1d2-Selected iNKT Cells. We
enriched PBS57-CD1d1+ cells from the thymus of B6 and
CD1D1−/− mice by using magnetic beads and analyzed the
maturation of iNKT cells by using the cell-surface markers
CD44 and NK1.1 to follow their maturation progress from stages
1 to 3 (40, 41). CD1d2-selected iNKT cells in CD1D1−/− mice
appeared less mature compared with CD1d1-selected iNKT cells
from B6 mice (Fig. 3A). Indeed, the majority of iNKT cells in the
CD1D1−/−mice were of the more immature stage 1 (CD44−NK1.1−)
or stage 2 (CD44+NK1.1−) phenotype compared with WT mice, in
which approximately 80% of cells are the most mature stage 3
(CD44+NK1.1+) phenotype (Fig. 3C). However, the absolute
number of iNKT stages detected in CD1D1−/− thymi was sig-
nificantly lower than that observed in control thymi as a result
of reduced total iNKT cell numbers in the CD1D1−/− mice.
Because analysis of iNKT cells by staging is insufficient, as
populations within each stage are heterogeneous (16, 42), we
also characterized the CD1d2-selected iNKT cells by their ex-
pression of the transcription factors PLZF, RORγt, and Tbet to
define terminally differentiated effector cells. Compared with
the iNKT subset makeup found in the B6 thymus, iNKT cells in
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Fig. 2. CD1D1−/−mice express low amounts of CD1dmolecules on the surface
of hematopoietic cells of the thymus, but not the periphery. (A) Flow-
cytometric analysis of CD1d levels of thymic DP (CD4+CD8+), CD4, and
CD8 subsets from C57BL/6 (black), CD1D1+/− (gray), CD1D1−/− (red), and
CD1D1D2−/− (blue) mice. (B) Flow-cytometry analysis of CD1d levels of spleen T
and B subsets derived from the aforementioned mouse strains. (C) Bars rep-
resent the relative gMFI of CD1d expression on total thymocytes, normalized
to C57BL/6. Bars depict mean ± SEM of at least three mice per group across at
least two experiments (***P < 0.001 by Student t test). (D) Bars represent the
relative gMFI of CD1d expression on total splenocytes, normalized to C57BL/6.
Bars depict mean ± SEM of at least three mice per strain across at least two
experiments. (E) Ratio of CD1D1/CD1D2-encoding transcripts in the thymus of
B6 and BALB/c mice. Primers containing specific Ion Torrent tags were
designed against segments identical in exon 2 of CD1D1 and CD1D2 genes.
CD69−CD4+CD8+ preselection DP thymocytes were sorted from three in-
dependent B6 and three independent BALB/c mice, and mRNA was extracted
and transformed into cDNA. CD1d exon sequence was amplified, and PCR
products were sequenced by using high-throughput sequencing. Transcript
identity was determined based on an 8-nt polymorphism (asterisk) that exists
between the two genes in this exon. The ratio of CD1D1 and CD1D2 mRNA
expression was significantly different between the two strains (P < 0.0001).
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the thymus of CD1D1−/− mice showed a trending increase in the
iNKT2 (PLZFhi, Tbetlo, RORγtlo) and iNKT17 (PLZFmid, Tbetlo,
RORγthi) populations and a concomitant decrease in iNKT1
(PLZFlo, Tbethi, RORγtlo) cells (Fig. 3 B and C). Interestingly,
even though the vast majority of the CD1d2-selected iNKT cells
are of the iNKT1 phenotype (i.e., PLZFlo Tbethi), these cells are
mostly NK1.1− and lack expression of the NK receptors Ly49C/I,
in striking contrast with the same population of iNKT1 cells in
B6 mice (Fig. 3B). This might have contributed to their lack of
detection in previous studies (33).
Next, we examined the Vβ repertoire expressed by iNKT cells
selected on CD1d1 in B6 mice or on CD1d2 in CD1D1−/− mice
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Fig. 3. Development and repertoire of CD1d2-selected iNKT cells. PBS57-CD1d1 tetramer-reactive thymocytes were enriched from C57BL/6 and pooled
CD1D1−/− thymi (≥5 mice per sample) by using MACS beads. Enriched cells were stained with indicated markers and assessed by flow cytometry to characterize
specific stages of iNKT-cell development (A) (data representative of n ≥ 3 per group) or functional subsets of iNKT cells as defined by the expression of the
transcription factors PLZF, RoRγt, and Tbet (B). (C) Graphs depict mean ± SEM of A and B (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; ns, not
significant). (D) PBS57-CD1d1 tetramer-reactive thymocytes were enriched by MACS beads from individual B6 or pooled CD1D1−/− thymi (≥5 mice per sample).
Enriched cells were stained with PBS57-CD1d1 tetramers, TCRβ, Vβ8, Vβ7, and Vβ2 mAbs and assessed by flow cytometry to characterize Vβ usage (data
representative of n ≥ 3 samples per group). Bars depict mean ± SEM of percentage of iNKT cells expressing each Vβ (*P < 0.05, **P < 0.01, ***P < 0.001, and
****P < 0.0001; ns, not significant). (E) Visual representation of Vβ8 CDR3 sequences from sorted iNKT cells of B6 (Left) and CD1D1−/− (Right) mice. Each
CDR3 sequence is represented by a dot, with the size of the dot proportional to the number of times this CDR3 sequence was found with the sample, and each
Jβ is represented by a color. Vβ8 rearrangements were amplified by PCR with a V-specific primer and a C-specific reverse primer followed by high-throughput
sequencing using the Ion Torrent platform. Sequence analysis was performed with in-house software, and gene identity was assigned on the basis of se-
quence alignment with published sequences (International ImMunoGeneTics Information System). (F) Vβ8 rearrangements from B6 and CD1D1−/− iNKT cells
were amplified and cloned into retroviral plasmids. Retroviruses were produced and used to transduce Vα14-expressing hybridoma. Hybridoma were sorted
for similar TCR expression and transduced with NFAT-GFP reporting construct. Antigen presentation assay using the B cell lymphoma CHB cells transfected or
not with CD1D1- or CD1D2-expressing constructs was performed. The percentage of GFP+ hybridoma cells from triplicate cultures was recorded by using flow
cytometry after 18 h of cultures and quantified (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by two-way ANOVA). Results are representative of
three independent experiments. (G) Intracellular IFN-γ expression of liver iNKT cells 7 h after LPS injection. iNKT cells were identified by using PBS57-
CD1d1 tetramer and TCRβ mAbs and stained intracellularly for IFN-γ. Plots are representative of at least three mice per group. (H) Bars depict mean ± SEM of
percentage of responding iNKT cells within each strain or condition (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; ns, not significant).
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by flow cytometry. Similar to what has been reported previously
for the CD1d1-selected iNKT repertoire (43, 44), CD1d2-
selected iNKT cells were enriched for Vβ8+ and Vβ7+ cells
compared with conventional T cells. However, a small but con-
sistent increase in the proportion of cells using the Vβ8 gene
segment, concomitant to a reduction in Vβ7 gene usage, was
observed for CD1d2-selected iNKT cells compared with CD1d1-
selected iNKT cells (Fig. 3D). To further compare the TCR
repertoires of CD1d1-selected and CD1d2-selected iNKT cells,
we sorted PBS57-CD1d1 tetramer+ cells from the thymi of two
C57BL/6 mice and more than 30 pooled CD1D1−/− thymi. Total
RNA was extracted, and cDNA was synthesized. We amplified
Vβ8.1/8.2 rearrangements by using specific Vβ8.1/2 and Cβ pri-
mers, and the PCR fragments were sequenced by using next-
generation sequencing. Fig. 3E presents a visual depiction of
all sequences found in the B6 and CD1D1−/− Vβ8+ iNKT rep-
ertoires, where every dot represents a unique CDR3β sequence,
the size of the dot represents how many times this sequence was
found, and the color represents which Jβ was used. As expected,
CD1d1-selected iNKT cells expressed a polyclonal repertoire
with no overrepresentation of any particular sequence (45). Al-
though the CD1d2-selected iNKT cell repertoire was also poly-
clonal, it appeared to be much more limited, with fewer clones
and fewer Jβs represented. In fact, when comparing the overlap
between the two repertoires, we observed that only 16% of the
sequences from CD1D1−/− iNKT cells were contained within the
B6 repertoire. Thus, the majority of Vβ8.1/8.2 TCR sequences
found in the iNKT cells from CD1D1−/− mice appear unique to
these iNKT cells. To further explore the antigen reactivity of
CD1d1 vs. CD1d2-selected iNKT TCR repertoires, we cloned li-
braries of Vβ8.1/8.2 TCR sequences into retroviral plasmids. We
then transduced a TCR-negative T hybridoma with the Vα14-Jα18
TCRα chain and the two different Vβ8 libraries derived from
B6 or CD1D1−/− iNKT cells. The hybridoma was further trans-
duced with a NFAT-GFP construct, allowing for measurement of
TCR stimulation on a per-cell basis. Hybridomas expressing Vβ8
TCR repertoires derived from B6 or CD1D1−/− mice were culti-
vated overnight in the presence of the CHB lymphoma that had
been previously transfected (or not) with CD1d1- or CD1d2-
expressing constructs. As seen in Fig. 3F, approximately 2% of
the hybridoma expressing the B6 iNKT cell repertoire expressed
GFP upon stimulation by CD1d-expressing APCs. The proportion
of autoreactive cells was increased to 4–5% of the cells when the
repertoire derived from CD1D1−/− iNKT cells was interrogated in
a similar fashion (Fig. 3F). Cell sorting of these GFP+ cells and
subsequent restimulation with CD1d-expressing APCs demon-
strated the autoreactivity of these cells toward CD1d-expressing
APCs. Altogether, these data suggest that the TCR repertoire of
iNKT cells found in CD1D1−/−mice is more autoreactive than the
TCR repertoire expressed by B6-derived iNKT cells. This might
be a result of the nature of the CD1d2 molecules themselves, al-
terations in the self-lipid repertoire, and/or their low levels of
expression in the thymus of CD1D1−/− mice (Fig. 2).
CD1d2-Selected iNKT Cells Are Functional. To test whether CD1d2-
selected iNKT cells were functional in vivo, we injected 2 μg of the
prototypic antigen αGC, which has a 26-carbon–long fatty acid
chain, i.v. to B6 and CD1D1−/− mice and harvested livers from the
animals 90 min later to interrogate IL-4 and IFN-γ production
within iNKT cells (44). Unlike B6 controls, in which 90% of
iNKT cells were activated as detected by IFN-γ intracellular cy-
tokine staining, no CD1D1−/−-derived iNKT cells were responsive
to injected antigen, resembling PBS solution-injected controls.
These results probably reflect the absence of the CD1d molecule
expression in the peripheral tissues required to present the antigen.
However, iNKT cells can also be activated in a TCR-independent
manner in response to inflammatory cytokines secreted by acti-
vated antigen-presenting cells (46, 47). Therefore, we injected 40
μg of LPS or PBS solution control to B6 or CD1D1−/− mice and
harvested their livers 7 h after injection. Cells were stained in-
tracellularly for IFN-γ directly ex vivo without further stimulation
and/or addition of Brefeldin A. Although the activation of iNKT
cells through LPS is less robust than through TCR engagement by
the αGC/CD1d complex, the results clearly demonstrated that
CD1d1-selected as well as CD1d2-selected iNKT cells could pro-
duce IFN-γ under these conditions (Fig. 3 G and H). These results
demonstrate that CD1d2-selected iNKT cells are functional and
capable of secreting cytokines upon stimulation. Furthermore,
these results support the idea that the maintenance of iNKT cell
effector function is TCR independent and does not require tonic
signaling mediated by CD1d molecules.
Overall Architecture of CD1d2. To gain insight into the detailed
architecture of the CD1d2 molecule, we expressed and purified
CD1d2 from the supernatant of insect cells and subsequently
determined its structure. CD1d2 adopted a standard MHC-I fold,
like CD1d1 (Fig. 4 and SI Appendix, Table S1). Similar to the
overall architecture of other CD1 molecules (48–51), the α1- and
α2-helices are positioned atop of a six antiparallel β-strands plat-
form to form a deep hydrophobic antigen-binding groove (∼1,300
Å3) that accommodates lipid-based antigens (Fig. 4A). Following
the nomenclature adopted for mouse CD1d1 (3), the antigen-
binding cleft is composed of two distinct A′- and F′-pockets
(Fig. 4 A and B) that differ in size and architecture. The contour of
the A′-portal (∼550 Å3) is delineated by a number of bulky hy-
drophobic residues (W40, F70, Y73, F77, F116, and W168) with
residues Y73 and F77 separating the A′-pocket from the F′-pocket
(Fig. 4B). The F′-pocket (750 Å3) is shaped by an extensive net-
work of hydrophobic residues. Here, residues L100, V118, F120,
A125, F128, and L143 form the floor of the pocket and a number
of key hydrophobic residues from the α1- and α2-helices (Y73,
F77, I81, L84, V85, M88, W142, L143, P146, I147, L150, and
T156) define the overall shape of the F′-pocket (Fig. 4B, Right).
The CD1d2 crystal structure also revealed clear separate un-
accounted and continuous electron density within the A′- and
F′-portals to protrude out of the binding cleft (SI Appendix,
Fig. S2). This density suggested the presence of an endogenous
bound lipid containing a head group that was acquired from
the Hi5 insect cells during the recombinant expression of CD1d2.
Although the precise identity of the endogenous ligand is un-
determined, we modeled in the unbiased electron density the
common self-membrane phospholipid phosphatidic acid (PA).
This enabled us to evaluate the approximate length of the acyl
chains that the endogenous lipid may contain. PA consisting of
two acyl chains composed of 10 and 18 carbons could accommo-
date the continuous electron density that was visible in the A′- and
F′-pockets, respectively (SI Appendix, Fig. S2).
To formally demonstrate that CD1d2 presents lipid antigens
of shorter acyl-chain length, we conducted lipid loading experi-
ments with a truncated analog of αGC in which the acyl chain
was 10 carbon atoms in length [αGC (C10)]. Although we could
not load recombinant CD1d2 with αGC, the αGC (C10) form
readily complexed with CD1d2. We then subsequently de-
termined the structure of CD1d2-αGC (C10; SI Appendix, Table
S1), in which the C10 acyl chain was clearly observed within the
A′-pocket of CD1d2. The structure of CD1d2-αGC (C10) was
very similar to that of CD1d2 bound to endogenous lipids, and
the mode of αGC (C10) presentation by CD1d2 was very similar
to that of CD1d1-αGC. Accordingly, CD1d2 can present αGC
(C10) in a manner analogous to CD1d1 presentation of α-GC.
Comparison of the CD1d2 and CD1d1 Crystal Structures. CD1d2 and
CD1d1 share high amino acid sequence identity (93%; SI Appendix,
Fig. S3) that is reflected by a very similar α1- and α2-domain ar-
chitecture with an rmsd of 0.9 Å over 178 Cα atoms (Fig. 4D). Thus,
the presence of the Cys168Trp polymorphism did not lead to
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gross conformational changes in the CD1d2 architecture. The
majority of the polymorphisms between CD1d1 and CD1d2 are
evenly distributed over the α2-helix and the six β-sheet platform,
whereas the α1-helix sequence is conserved between CD1d1 and
CD1d2 (Fig. 4D and SI Appendix, Fig. S3). Ten of these poly-
morphic residues are located on the molecular surface of CD1d2
(SI Appendix, Fig. S4A). The remaining six residues (I30, T102,
F116, W168, and A172 in CD1d2) are predominantly buried
within the A′-pocket of CD1d2 (Fig. 4D and SI Appendix, Fig.
S4B). Interestingly, residues I30, T102, F116, and W168 are di-
rectly implicated in remolding the overall architecture of the
A′-portal relative to CD1d1 (Figs. 4E and 5A and SI Appendix,
Fig. S4B). The substitution of V30, L116, and C168 in CD1d1 by
the bulkier hydrophobic I30, F116, and W168 residues in CD1d2,
respectively, contributes to a reduction of the A′-pocket volume of
CD1d2 by ∼400 Å3 compared with CD1d1, and also serves to pre-
vent the collapse of the A′-pocket as a result of the lack of the in-
termolecular disulfide bond. Here, to accommodate the endogenous
lipid and αGC (C10), the side chain of F70 was repositioned in close
vicinity of I30 and W168 (∼4 Å distance), and consequently this
triad of residues contributed to restrict the size of the A′-portal
(Figs. 4E and 5A). Accordingly, the structural rearrangement in-
curred by these polymorphic residues may impact the overall
repertoire of lipids that can be presented by CD1d2 compared
with CD1d1. Modeling of longer acyl chains in the A′-pocket was
sterically disfavored by the architecture of the CD1d2 groove (Fig.
5 C and D). Indeed, the A′-pocket of CD1d2 favors the loading of
shorter sized lipids compared with that of CD1d1, as evidenced by
the CD1d2-αGC(C10) structure. In the CD1d2 A′-pocket, resi-
dues T102 and F116 also impacted the overall position of the
acyl chain of the endogenous lipid (Fig. 5B). By contrast, the
F′-pockets of CD1d2 and CD1d1 are highly conserved (Fig. 4D)
whereby only A125 (CD1d2) was replaced by V125 (CD1d1; Fig. 4
D and E). Thus, molecular insights into the antigen-binding cleft
of CD1d2 show that lipid antigens with long acyl chains are not as
efficiently presented compared with CD1d1 molecules.
Fig. 4. CD1d2 crystal structure. (A) Cartoon representation of the CD1d2 crystal structure. CD1d2 and β2m are colored in gray and light orange, respectively.
(B) Close-up views of the A′- (Left) and F′-pockets (Right) of CD1d2. Both pockets are colored in pale green and shown as surface representations. (C, Left)
Unbiased Fo-Fc electron density map (magenta) contoured at 2.0σ level of the αGC (C10) lipid Ag. (C, Right) 2Fo-Fc electron density map (marine) contoured at
0.8σ level of the αGC (C10) lipid Ag. The lipid Ag is shown as black sticks. For clarity, only the α1- and α2-helices of CD1d2 are colored in light gray and shown as
cartoon representations. (D) Superimposition of the α1- and α2-domains of the crystal structures of CD1d2 (gray) and CD1d1 (PDB ID code 1CD1; light blue)
(48). The polymorphic residues between CD1d2 and CD1d1 are shown as sticks. For clarity, only the residues located inside the binding groove are shown. (E)
Surface representation of the binding pocket of CD1d2 (light green) and CD1d1 (pale yellow). A superimposition of the α1- and α2-domains of CD1d2 (gray)
and CD1d1 (light blue) is also shown.
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Differential Antigen Presentation by CD1d1 and CD1d2 Molecules. To
test the antigen-presentation ability of CD1d1 and CD1d2 molecules,
we cultivated hybridoma cells expressing a library of iNKT TCRs
(expressing different TCRβ chains) derived from B6 thymic
iNKT cells with B cell lymphoma CHB cells expressing similar levels
of CD1d1 or CD1d2 molecules. Increasing concentrations of various
antigens were added to the cultures, and the percentage of
GFP+ hybridoma cells was assessed after 18 h. As seen in Fig. 6,
CD1d2-expressing CHB cells poorly stimulated the hybridomas
compared with CD1d1-expressing cells when cultivated in the
presence of glycolipid antigens with long acyl chains, including
the prototypical iNKT antigen αGC (C26), the αGC variant
with a shorter sphingosine chain OCH9 (C24), and the Sphin-
gomonas-derived antigen GSL-1 (C14). In striking contrast, a
version of αGC with a 10-carbon acyl chain, or the α-psychosine
antigen, which lack an acyl chain (52, 53), equivalently stimulated
the hybridoma when cultivated with CD1d1- or CD1d2-expressing
cells. The β-anomeric form of psychosine did not stimulate the hy-
bridoma when cultivated with either APCs. CHB cells expressing
CD1d1 molecules with the Cys168→Trp168 mutation were also
poor presenters of αGC (C26) but could present αGC (C10) as
efficiently as WT CD1d1 molecules (Fig. 6). Altogether, these re-
sults suggest that CD1d2 molecules are poor presenters of long
acyl chain glycolipid antigens but can present certain antigens with
short acyl chains as efficiently as CD1d1 molecules. These results
demonstrate that both CD1d molecules in mice are not equivalent
and can selectively present different lipid antigens to iNKT cells.
CD1d2-αGC-C10 Tetramer+ Cells. Having established that CD1d2
molecules preferentially present glycolipid antigens with short
acyl chains, we loaded soluble CD1d2 monomers with αGC(C10)
and generated CD1d2 tetramers. Thymocytes from BALB/c, B6,
CD1D1−/−, and Jα18−/− mice were independently stained by using
the PBS57-CD1d1 or the αGC(C10)-CD1d2 tetramers (Fig. 7A).
The percentage of cells stained in each thymus was essentially
identical between tetramers, even though αGC(C10)-CD1d2 tetra-
mers stained with lower intensity compared with PBS57-CD1d1
tetramers. Costaining with saturating concentrations of CD1d1 and
CD1d2 tetramers loaded with PBS57 or αGC(C10), respectively,
were initially unsuccessful because no CD1d2 signal was detected in
these instances (data not shown). However, sequential staining with
the two tetramers could be achieved if CD1d2 tetramers were used
first. With the use of this strategy, we did not detect a significant
population of αGC(C10)-CD1d2-specific cells (Fig. 7B). Instead, a
fraction of iNKT cells was stained with both tetramers, whereas
some PBS57-CD1d1 tetramer+ cells were not labeled with the αGC
(C10)-CD1d2 tetramer. Interestingly, cells labeled with the αGC
(C10)-CD1d2 tetramer expressed the highest levels of TCR on their
surface (Fig. 7B), suggesting that the αGC(C10)-CD1d2 binds
only to the highest avidity iNKT TCRs.
Discussion
Peptide-presenting major histocompatibility molecules are
encoded by the most polymorphic genes in the genome. Most of this
polymorphism involves residues that are lining the antigen-binding
groove of MHC molecules (54). At the population level, these
polymorphisms provide various possible binding solutions to
the myriad of antigenic peptides that need to be presented for
immunosurveillance by T cells. By contrast, lipid-binding
CD1 molecules are essentially monomorphic, with the number
and complexity of CD1-encoding genes varying greatly between
species. The functional consequence of expressing multiple CD1
proteins presumably reflects pathogen-driven evolutionary pres-
sure. The mouse genome contains two genes, CD1D1 and CD1D2,
which encode for the CD1d molecules. A collection of observa-
tions had contributed to the misleading idea that CD1D2 might
not play any relevant role in the biology of lipid-reactive T cells.
By contrast, we now show that, in the 129/Sv and BALB/c mouse
strains, the CD1D2 gene is functional, and, in BALB/c mice, is
expressed equivalently to the CD1D1 gene at the mRNA level in
the thymus. The reason why CD1d2 protein expression was de-
tected in the thymus of CD1D1−/− mice (albeit at low levels) but
not in splenocytes is uncertain. Early experiments examining the
pattern of CD1d expression in whole organs or in cell lines sug-
gested that it was controlled, at least in part, at the transcrip-
tional level (19, 55). Our current understanding of CD1D
Fig. 5. Structural comparison between CD1d1 and CD1d2. (A) Close-up view
of a superimposition of the A′-pockets of CD1d1 and CD1d2 shown in yellow
and light green, respectively. (B and C) Superimposition of CD1d-
phosphatidylcholine (orange; PDB ID code 1ZHN) (71), CD1d-dioleoyl-PA (teal;
PDB ID code 4MX7), CD1d-αGC (C25; violet; PDB ID code 3HE6) (9), and CD1d2-
αGC (C10; black). (D) Close-up view of A. The α1- and α2-domains of the CD1d2
(gray) and CD1d1 (light blue; PDB ID code 1ZHN) are shown in each image.
CD1d1
CD1d2
CD1d1(C168W)
αGC (C26) OCH9 αGC (C10)
GSL-1 α-psychosine β-psychosine
%
 o
f G
FP
+ 
ce
lls
Concentration (ng/ml)
0 200 600 1000 0 200 600 1000 0 200 600 1000
0
50
100
0 5 100 50 150 2500 5 10
0
50
100
Fig. 6. Differential antigen presentation by CD1d1 and CD1d2 molecules.
Hybridoma-expressing Vβ8+ iNKT TCRs derived from C57BL/6 iNKT cells were
cultivated for 18 h with CHB cells stably transfected with CD1D1 (black),
CD1D2 (red), or the CD1D1mutant in which the cysteine 168 was replaced by
a tryptophan (green) and the indicated glycolipid antigens. Graphs depict
the percentage of GFP+ hybridoma as a function of antigen concentration.
Data represent the mean of duplicates for each condition and are repre-
sentative of three independent experiments.
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transcriptional regulation remains limited. The minimal promoter
region within 200 bp from the transcriptional start site of CD1D1
has been identified and was shown to be regulated by the Ets
family of transcription factors in B and myeloid cells (55). How-
ever, examination of the upstream DNA sequence of CD1D2
revealed that it is highly conserved with CD1D1, including the
previously identified Ets binding site. It is possible that thymocytes
express unique combinations of Ets transcription factors that allow
for the transcription of CD1d2. Lineage-specific regulatory elements
could also differentially control the expression of CD1D2 and
CD1D1 in different cell types. What advantage, if any, differential
CD1d2 expression between the thymus and other tissues might
provide remains to be determined. Irrespective of its low level of
expression in the thymus of CD1D1−/− mice, CD1d2 molecules are
clearly capable of selecting some iNKT cells in these mice. Conse-
quently, mice lacking only the CD1D1 gene (32) should not be
considered as NKT cell-deficient.
Interestingly, the phenotype and repertoire of the CD1d2-
selected iNKT cells in CD1D1−/− mice was not equivalent to
the CD1d1-selected iNKT cells in B6 mice. The iNKT cells in the
thymus of CD1D1−/− mice were somewhat enriched for the
iNKT2 and iNKT17 subsets compared with the subset com-
position encountered in age-matched B6 mice. Furthermore,
the thymic iNKT1 subset in CD1D1−/− mice expressed little to no
NK1.1 molecules, which usually characterize this subset in B6 mice.
Similarly, the Vβ repertoire of CD1d2-selected iNKT cells was
enriched for usage of the Vβ8 chain with a concomitant decrease in
Vβ7 usage compared with the CD1d1-selected iNKT cells. Pre-
vious reports showed that changes in Vβ selection occurred in mice
expressing lower or higher levels of CD1d, and reflected changes in
positive and negative selection according to Vβ affinities for self-
ligand presented by CD1d molecules (56, 57). The TCR Vβ domain
influences the thymic selection of iNKT cells by contributing to the
avidity of iNKT TCR binding to CD1d complexed with endogenous
ligand(s) (8). In heterozygote CD1D+/− mice that express half the
levels of CD1d compared with WT mice, Vβ7+ iNKT cells were
overrepresented with a concomitant decrease in Vβ8 usage, sug-
gesting that Vβ7-containing iNKT TCRs have higher affinity for
the self-ligand(s)–CD1d complexes that are responsible for the
positive selection of these cells. By contrast, in CD1D1−/− mice,
the expression level of CD1d2 was only 4% of the level of CD1d
observed in WT mice, and yet we observed a preferential en-
richment of Vβ8+ iNKT cells. Sequencing of the CDR3 region of
these Vβ8+ iNKT cells demonstrated poor overlap with the rep-
ertoire of B6 Vβ8+ iNKT cells. Furthermore, the CD1d2-selected
Vβ8 iNKT repertoire tended to be more autoreactive when
reexpressed in an in vitro system. The reason(s) for these differ-
ences remains unclear. It is possible that the low level of CD1d2
expression contributed to the selection of iNKT cells expressing
TCR of the highest avidity, which would otherwise be negatively
selected in WT animals. Alternatively, the presentation of a dif-
ferent set of self-antigen(s) responsible for the positive selection of
iNKT cells between CD1d1 and CD1d2 could contribute to these
differences in repertoire and phenotype. These two possibilities
are not exclusive. Future experiments aimed at manipulating the
expression level of CD1d2 to match the levels observed for CD1d1
should be informative in that matter.
One aspect that determines the function of a CD1 protein is
the size and shape of the antigen-binding groove. For example,
human CD1b has a large antigen-binding groove that can ac-
commodate ligands of as much as 80 carbon atoms in length (49).
In contrast, the human CD1a isoform has a unique architecture
that appears to favor “headless” antigens, with a restricted A′-
pocket that prefers lipids of shorter acyl-chain length (C18–C20)
(50, 58). Our work resonates with the CD1a molecule in that
CD1d2 favors the presentation of shorter length lipid ligands in
comparison with CD1d1. Despite high homology between the
two CD1d molecules, changes in amino acids at position I30,
T102, F116, and especially W168 restrict the size of the A′-pocket
of CD1d2. The Trp-168 blocks part of the A′-pocket so that long
fatty acid chain glycolipids will not fit. In agreement with the
structural data, APCs engineered to express the CD1d2 molecules
or the C168W CD1d1 mutant were poor presenters of common
glycosphingolipids, including the prototypical antigen αGC, which
consist of fatty acid with a length of 24–26 carbons. Interestingly,
comparable observations had been previously reported whereby
the equivalent cysteine residue in the bovine CD1d and the an-
cestral chicken CD1-2 are replaced by a tryptophan and phenyl-
alanine, respectively (26, 27). These restricted the size of the A′-
pocket of the two isoforms and reduced their capacity to bind long-
chain lipid-based antigens (26, 27). Similarly, CD1d2 molecules
efficiently presented only glycolipid antigens with short or no acyl
chains. Of interest, α-psychosine, which contains a single lipid chain
and has been proposed to possibly play a role in the selection of
iNKT cells (52), was presented well by both CD1d molecules.
Although the lipid portions of antigens are buried in the CD1d
groove, the composition of the fatty acids, including the length, the
degree of unsaturation, and the presence of other modifications,
strongly influences antigenic potency (59–61). As such, it is rea-
sonable to hypothesize that the balance between the various anti-
gen species that might be presented by CD1d1 and/or CD1d2 in
the thymus possibly affects the tuning of the iNKT TCR repertoire
to different ligands. CD1d2 might also be important in shaping
the repertoire of other CD1d-restricted T cells.
Methods
Mice. The CD1D1−/− (32), CD1D1−/−CD1D2−/− (30), and Jα18(neo) (36) mice
have been described previously and were backcrossed >10 times on the
C57BL/6 background. C57BL/6 and BALB/c were purchased from Jackson
Laboratories. All mice were used between 6 and 12 wk and were age-matched
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Fig. 7. αGC(C10)-CD1d2 tetramer staining. (A) Thymocytes from BALB/c, C57BL/
6, CD1D1−/− and Jα18−/−mice were stained with CD1d1 tetramers loaded (or not)
with PBS57 or CD1d2 tetramers loaded (or not) with αGC (C10) and TCRβ mAbs.
The percentage of tetramer+ is shown. Data are representative of two in-
dependent experiments. (B) Thymocytes from the aforementionedmouse strains
were first stained with αGC (C10)-CD1d2 tetramers, washed, and subsequently
stained with PBS57-CD1d1 tetramers. Data are representative of three in-
dependent experiments. Simultaneous staining with both tetramers did not al-
low for the detection of the fluorophore associated with the CD1d2 tetramer.
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for each experiment. All mice were raised in a specific pathogen-free envi-
ronment at the Biology Resource Center at National Jewish Health (NJH) and
the Office of Laboratory Animal Research at the University of Colorado Denver
(UCD). All animal procedures were approved by the NJH (protocol AS2780-10-
16) and UCD [protocol B-64314(05)1E] Institutional Animal Care and Use
Committees and were carried out in accordance with the approved guidelines.
Lymphocyte Isolation. Single-cell suspensions were prepared from the thymus,
spleen, and liver by manual disruption by using a syringe plunger. The liver
was perfused with PBS solution and then cut into small pieces, disrupted with
a syringe plunger, and liver lymphocytes were isolated by centrifugation by
using a 33% (vol/vol) Percoll gradient (GE Healthcare).
High-Throughput Sequencing. CD69−CD4+CD8+ preselection double-positive
thymocytes were sorted by flow cytometry and washed twice in ice-cold
PBS solution. Total RNA was extracted by using the RNeasy Mini Kit
(Qiagen). cDNA was made by using SuperScript III Reverse Transcriptase
(Invitrogen). The Vβ8-Cβ region was amplified by using specific Vβ8 (5′-
ATTATTCATATGGTGCTGGC-3′) and Cβ (5′-CGATCTTGGGTGGAGTCACATTTC-
TC-3′) primers with required specific Ion Torrent tags. Purified PCR products
were sent for high-throughput sequencing by using the Ion Torrent plat-
form. Sequence analysis was done with in-house software, and gene identity
was assigned on the basis of sequence alignment with published sequences
(International ImMunoGeneTics Information System).
Alternatively, exon 2 of CD1d genes was amplified by PCR with Phusion high-
fidelity polymerase (NEB) using specific primers (forward, 5′-TACACCTTCCGC-
TGCCT-3′ reverse, 5′-AGCTACTCGATAGACTTGAAAC-3′) with required specific Ion
Torrent tags. Gel-purified PCR products were sequenced with the Ion Torrent
platform. Sequence analysis was done with in-house software, and gene identity
was assigned on the basis of sequence alignment with published sequences.
Quantitative PCR. Total mRNA was extracted from sorted cells by using TRIzol
solution (Invitrogen). RNA was treated with the DNA-free kit (Ambion) to
remove contaminating DNA from RNA preparations. Reverse transcription
was carried out by using the SuperScript III Kit (Invitrogen) following the
manufacturer’s instructions. The amount of amplicon generated during the
PCR was monitored with a DNA engine Opticon 2 apparatus (MJ Research)
by using gene-specific primers and probes and Platinum Quantitative PCR
SuperMix UDG (Invitrogen). The sequences of the primers and probes are as
follows: Vα14 forward, 5-TACAGTGTGACCCCCGACAAC-3; Cα forward,
5-CCTCTGCCTGTTCACCGACTT-3; Cα reverse, 5-TGGCGTTGGTCTCTTTGAAG-3; Cα
probe, 5 FAM-CTCCCAAATCAATGTGCCGAAAACCA-TAMRA-3; Vα14 probe, 5
FAM-CACCCTGCTGGATGACACTGCCAC-TAMRA-3; and Jα18 probe, 5 FAM-
AGCTGGGACTCAGCTGATTGTCATACCTG-TAMRA-3.
Flow Cytometry. PBS57-CD1d1 tetramer was obtained from the National
Institutes of Health Tetramer Core Facility. The complete list of surface an-
tibodies used is as follows. From BD Biosciences, anti-TCRβ (H57-597), anti-
CD8α (53-6.7); from BioLegend, mCD1d (1B1), CD44 (IM7); from eBioscience,
anti-B220 (RA3-6B2), anti-MHCII (I-A/I-E; M5/114.15.2), anti-CD4 (RM4-5), and
anti-NK1.1 (PK1316). Surface antibody staining was done and then cells were
fixed and permeabilized by using the FoxP3 buffer set (eBioscience). Fixed
and permeabilized cells were incubated with intracellular antibodies in-
cluding anti-PLZF (Mags.21F7; eBioscience), anti-Tbet (4B10; BioLegend),
anti-RORγt (Q31-378; BD Biosciences), or anti–IFN-γ (XMG1.2, eBioscience).
Cells were analyzed on a BD LSRFortessa device (BD Biosciences), and data
were processed with FlowJo software (TreeStar).
Enrichment of CD1d Reactive Thymocytes. Thymocytes were enriched for
PBS57-CD1d reactive cells by incubating thymocyte cell suspensions with PE-
or APC-conjugated PBS57-CD1d tetramers for 45 min at 4 °C, incubated with
anti-PE or anti-APC magnetic microbeads (Miltenyi Biotec) for 15 min at 4 °C,
followed by separation by using an autoMACS Pro Separator (Miltenyi Bio-
tec) according to the manufacturer’s instructions. Cells were then later
surface-stained and then intracellular-stained for flow cytometry.
In Vivo iNKT Cell Stimulation. Mice were administered vehicle or 2 μg αGC
(Funakoshi) by i.v. injection. Organs (spleen or liver) were harvested 90 min
post injection. Cells were then later surface-stained and then intracellular-
stained for flow cytometry without the use of Brefeldin A or further acti-
vation. Mice were administered PBS solution or 40 μg LPS (Sigma) by i.v.
injection. Livers were harvested 7 h post injection. Cells were surface-stained
and then intracellular-stained for flow cytometry.
TCRβ Library Preparation and T Cell Hybridoma. The 58α−β− hybridoma cell line
(62) was infected with hCD4-pA-GFP-NFAT-RV (63), and then cells positive for
human CD4 were sorted by using an Aria cell sorter 2 d after transduction.
Cells were next transduced with Vα14 iNKT TCRα chain-IRES-NGFR retrovirus,
and cells positive for NGFR were sorted. Vβ8+ TCR rearrangements were am-
plified from total iNKT cells purified from the thymus of B6 or CD1D1−/− mice
and cloned into retroviral plasmids as previously described (8). Cells were
transduced with the retroviral TCRβ libraries, and TCRβ+ cells were sorted to
obtain TCRαβ+ cells. TCR-reconstituted hybridomas (2.5 × 104 cells) were cul-
tured for 18 h with antigens and CHB (5 × 105 cells) in 96-well round-bottomed
plates. GFP expression on the hybridomas was analyzed by flow cytometry.
CHB Transfectants. cDNA encoding CD1d1 and CD1d2 molecules were amplified
from B6 or CD1D1−/− splenocytes by using the primers 5′-ATTTATCTCGAGC-
CACCATGCGGTACCTACC-3′ and 5′-ATTAAAGAATTCTCACCGGATGTCTTGA-
TAAGCGC-3′ and cloned into retroviral plasmids. Plasmids were sequence-
verified, and retroviruses were prepared as previously described (8) and used to
transduce CD1d-negative CHB B cell lymphoma (64). Stably transduced cells were
sorted for similar CD1d cell surface expression by flow cytometry by using an Aria
cell sorter (BD Bioscience). The C168W CD1D1 mutant was generated by using
QuikChange II Site-Directed Mutagenesis Kit following the manufacturer’s
instructions. CHB cells expressing the C168W mutant were generated similarly.
Cloning, Expression, and Purification of CD1d2. The mouse CD1d2/β2m gene (129/Sv
sequence) harboring BirA and 6×-histidine tags was cloned into the baculovirus
pFastBac Dual Expression vector as previously described (65). The CD1d2/β2m
glycoprotein was expressed for 72 h at 23°C by using High Five expression insect
cells. The baculovirus-expressed soluble CD1d2/β2m protein was then concen-
trated and buffer was exchanged against 20 mM Tris, pH 8.5, 500 mM NaCl, and
purified by Ni-NTA. The protein was then dialyzed against 20 mM Tris, pH 8.5,
150 mM NaCl, and further purified by size-exclusion chromatography.
Crystallization and Structure Determination of CD1d2. The purified CD1d2 protein
and CD1d2-αGC (C10) complex (8–10 mg/mL) in 20 mM Tris, pH 8.5, 150mMNaCl
was crystallized in 26% PEG 3350, 0.1 M Bis-Tris, pH 6, 0.2 M CaCl2 at 20 °C by
using the hanging-drop vapor-diffusion method. The crystals were flash-frozen
before data collection in mother liquor containing 10–15% glycerol as a cryo-
protectant. The crystals of CD1d2 were diffracted at the Australian Synchrotron
facility (Melbourne, Australia). The dataset was processed and scaled by using
the programs iMosflm and SCALA from the CCP4 suite, respectively (66–68). The
crystals diffracted to 2.3-Å resolution and belonged to the space group of P21
with two molecules in asymmetric unit. The crystal structures of CD1d2 and
CD1d2-αGC(C10) were determined by molecular replacement by using the
Phaser-MR program (69) using the mouse CD1d1 as search model [Protein Data
Bank (PDB) ID code 1CD1] (48). The model building and subsequent refinement
cycles were performed with the program COOT (70) and the refinement program
BUSTER 2.10 (https://www.globalphasing.com/buster/), respectively. The quality of
the final structure was validated by using the PDB validation server from the PDB
database (https://validate-rcsb-1.wwpdb.org/). The coordinates relating to the data
reported in this study are deposited in the PDB database with ID codes 6BMH
(CD1d2-αGalCer C10 structure) and 6BMK (CD1d2-PA C10 structure, endogenous).
Biotinylation of CD1d2. For the purpose of biotinylation, the purified
CD1d2 was desalted and incubated eight parts of CD1d2 with one part of
buffer A (100 mM Bicine, pH 8.3) and one part of buffer B (100 mM ATP,
100 mM MgOAc, 500 μM D-biotin) along with 2 μL of biotin protein ligase
(1 mg/mL). The biotinylation reaction was carried out at room temperature
overnight. The excess of free biotin was removed by size-exclusion chro-
matography by using a Superdex 200 10/30 gel filtration column.
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